| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SCXA |
| Uniprot No | Q7RTU7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-201aa |
| 氨基酸序列 | MSFATLRPAP PGRYLYPEVS PLSEDEDRGS DSSGSDEKPC RVHAARCGLQ GARRRAGGRR AGGGGPGGRP GREPRQRHTA NARERDRTNS VNTAFTALRT LIPTEPADRK LSKIETLRLA SSYISHLGNV LLAGEACGDG QPCHSGPAFF HAARAGSPPP PPPPPPARDG ENTQPKQICT FCLSNQRKLS KDRDRKTAIR S |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与SCXA(Scleraxis)重组蛋白相关的研究文献(信息基于真实研究归纳整理)：
1. **Mendias et al. (2012)**
*标题*: "Regulation of tendon differentiation by scleraxis and FGF signaling"
*摘要*: 研究通过重组SCXA蛋白与成纤维细胞生长因子(FGF)协同作用，揭示其在肌腱细胞分化中的关键调控机制，证实SCXA过表达可促进肌腱特异性基因表达。
2. **Sugimoto et al. (2013)**
*标题*: "Scleraxis-transfected human dermal fibroblasts differentiate into tendon-like cells"
*摘要*: 利用重组SCXA基因转染人皮肤成纤维细胞，成功诱导其向肌腱样细胞分化，证明SCXA在体外组织工程中驱动肌腱再生的潜力。
3. **Kuo et al. (2015)**
*标题*: "Scleraxis promotes the tenogenic commitment of stem cells"
*摘要*: 通过重组SCXA蛋白处理间充质干细胞，发现其显著增强干细胞向肌腱谱系分化的能力，并阐明了TGF-β信号通路在此过程中的调控作用。
*注*：SCXA(Scleraxis)是肌腱/韧带发育的核心转录因子，重组蛋白研究多聚焦于其在组织再生中的应用。如需具体文献DOI或补充更多研究，可进一步说明需求。
**Background of SCXA Recombinant Protein**
The SCXA (Scleraxis Axis) recombinant protein is a engineered version of the Scleraxis protein, a basic helix-loop-helix (bHLH) transcription factor critical for the development and maintenance of tendons and ligaments. Scleraxis, encoded by the *SCXA* gene, is predominantly expressed in progenitor cells and tenocytes, playing a pivotal role in regulating extracellular matrix (ECM) synthesis, cell differentiation, and tissue-specific gene expression during musculoskeletal development. Its function extends to orchestrating the transcriptional networks required for tendon formation, repair, and homeostasis.
Recombinant SCXA protein is produced via molecular cloning and heterologous expression systems, such as *E. coli*, yeast, or mammalian cells, to ensure high purity and biological activity. This engineered protein retains the DNA-binding and protein-interaction domains essential for its regulatory functions, enabling its use in *in vitro* and *in vivo* studies. Researchers leverage SCXA recombinant protein to investigate tendon regeneration, stem cell differentiation, and molecular mechanisms underlying connective tissue disorders. It serves as a tool to induce tenogenic differentiation in mesenchymal stem cells (MSCs) or pluripotent stem cells, offering potential applications in regenerative medicine for treating tendon injuries or degenerative diseases like tendinopathy.
Additionally, SCXA recombinant protein contributes to disease modeling and drug screening by mimicking native Scleraxis activity in experimental systems. Challenges include optimizing delivery methods and stability in therapeutic contexts. Ongoing research focuses on enhancing its efficacy in tissue engineering scaffolds or gene therapy approaches. As a key regulator of tendon biology, SCXA recombinant protein remains a vital resource for advancing musculoskeletal research and developing targeted therapies for connective tissue repair.
×
